title: Acute infusion reactions to chemotherapeutic drugs: a single institute experience.
abstract: OBJECTIVE
  Treating cancer often involves the use of chemotherapeutic agents. Due to the growing incidence of cancer worldwide and the expanding number of treatment options, it is important to understand the risks of adverse events associated with these treatments. In this study, we monitored the occurrence of acute infusion reactions in an outpatient chemotherapy center from April 2011 to April 2012.
  
  
  METHODS
  For patients who developed infusion reactions, the causative drug, the dose and number of treatments received, the onset time of the reaction, the duration of the reaction, blood pressure, pulse, level of oxygen saturation during the reaction, and other symptoms were recorded. The severity of reactions was determined in accordance with NCI toxicity criteria. A reaction was considered as grade 1-2 (mild-moderate) if the patient experienced flushing, rash, fever, tremor, dyspnea, rigor, and mild hypotension. Symptoms such as severe hypotension, bronchospasm, cardiac dysfunction and anaphylaxis, requiring therapeutic intervention, were classified as severe, grade 3-4 reactions.
  
  
  RESULTS
  Of the 2213 patients receiving chemotherapy during the study period, 138 (62%) developed an infusion reaction to the treatment. Among 138 patients most commonly treated types of carcinoma included breast (39.2%), lung (17.8%), colorectal (10%), and ovarian (8.5%) cancers. Docetaxel administration resulted in the largest number of infusion reactions, though most reactions were mild to moderate and did not require the cessation of treatment. Patients with mild to moderate reactions (89.2%) were able to continue treatment, while those who developed severe reactions (10.8%) could not continue treatment with the same agent.
  
  
  CONCLUSIONS
  Although severe reactions are rare, the incidence of mild to moderate reactions against taxanes, platinum compounds, and monoclonal antibodies is quite high. Clinical symptoms do not vary widely among the agents, though the onset time of symptoms does vary. While reactions against platinum agents were of type 1 anaphylactic reactions, reactions against taxanes and monoclonal antibodies during the first infusion and in the following minutes suggest the activation of different mechanisms.
authors.affiliation: Baskent University School of Medicine Department of Medical Oncology, Adana, Turkey. smuallaoglu@hotmail.com
authors.forename: S
authors.initials: S
authors.lastname: Muallaoglu
authors.forename: U
authors.initials: U
authors.lastname: Disel
authors.forename: H
authors.initials: H
authors.lastname: Mertsoylu
authors.forename: A
authors.initials: A
authors.lastname: Besen
authors.forename: C
authors.initials: C
authors.lastname: Karadeniz
authors.forename: A
authors.initials: A
authors.lastname: Taner Sumbul
authors.forename: H
authors.initials: H
authors.lastname: Abali
authors.forename: O
authors.initials: O
authors.lastname: Ozyilkan
mesh_terms: D000208:Acute Disease; D000328:Adult; D000368:Aged; D000553:Ambulatory Care; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D004342:Drug Hypersensitivity / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology*; D064420:Drug-Related Side Effects and Adverse Reactions / Q000139:chemically induced* / Q000175:diagnosis / Q000453:epidemiology; D005260:Female; D006801:Humans; D015994:Incidence; D007263:Infusions, Parenteral; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012307:Risk Factors; D012720:Severity of Illness Index; D013997:Time Factors; D014421:Turkey / Q000453:epidemiology
chemical_list: D000970:Antineoplastic Agents